With detailed methods and protocols, contributors address computational strategies, a number of assay methods (for DNA gyrase, topoisomerase IV, bacterial RNA polymerase, bacterial ribosome biogenesis and inhibitors targeting specific translational steps), high-throughput peptide deformylase
inhibitor screening, penicillin-binding protein assay methods, methods for assessing the structure and function of cationic antimicrobial peptides, and bacterial efflux pump inhibitors.
Nasdaq: MICU; Nuovo Mercato) announced today that the company has received another milestone payment from Novartis Pharma AG in recognition of follow-up lead product candidates identified for Novartis' development from its ongoing research collaboration focused on peptide deformylase
inhibitors, a novel class of antibiotics.
A new class of drugs known as peptide deformylase
inhibitors could help overcome bacterial resistance to antibiotics, Dr.
an Antibiotic Program based on peptide deformylase
The lead compounds in British Biotech's in-house antibiotic programme are peptide deformylase
inhibitors in development for respiratory tract and other gram positive infections.
In pre-clinical studies the Antibiotic Program's lead compounds, peptide deformylase
(PDF) inhibitors, have shown high potency against gram positive bacteria, in particular drug-resistant strains of Streptococcus pneumoniae.
The Company's preclinical program includes an oral peptide deformylase
(PDF) inhibitor series, under preclinical development for community-based respiratory tract infections.
In addition, data from our collaborations with Novartis in peptide deformylase
inhibitors and Pfizer in oxazolidinones also will be presented.
In October 2003 Vernalis' peptide deformylase
inhibitor research programme in the antibiotic field was out-licensed to Genesoft Pharmaceuticals Inc.
1 million in cash through public offering of six million shares of common stock -- Added senior management in sales and marketing to spearhead anidulafungin launch -- Achieved milestone as Novartis moved innovative peptide deformylase
inhibitors for community based bacterial infections into Phase I About Vicuron
The focus of this research collaboration is the discovery of peptide deformylase
inhibitor antibacterial agents for the community market.
Achieved another milestone in ongoing research collaboration with Novartis Pharma AG to develop oral peptide deformylase
inhibitor antibiotics in preparation for first of these compounds to enter the clinic.